Onvansertib in Combination With Gemcitabine and Nab-paclitaxel for the Treatment of Patients With Locally-advanced, Unresectable, or Metastatic Pancreatic Ductal Adenocarcinoma

Clinical trial NCT06398587 · WITHDRAWN

Trial details

NCT number: NCT06398587
Sponsor: OHSU Knight Cancer Institute
Status: WITHDRAWN
Phase: Phase 2
Study type: INTERVENTIONAL

Locally Advanced Pancreatic Ductal Adenocarcinoma Metastatic Pancreatic Ductal Adenocarcinoma Stage II Pancreatic Cancer AJCC v8 Stage III Pancreatic Cancer AJCC v8 Stage IV Pancreatic Cancer AJCC v8 Unresectable Pancreatic Adenocarcinoma

Start date: 2024-08-01
Primary completion: 2026-05-04
Enrollment: 0

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.